TEVA PHARMACEUTICAL INDUSTRIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.81 USD | +4.23% |
|
+7.39% | +32.28% |
| Sales 2024 * | 15.86B 1,270B | Sales 2025 * | 16.35B 1,309B | Capitalization | 15.64B 1,252B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.54B 123B | Net income 2025 * | 1.44B 115B | EV / Sales 2024 * | 1.91 x |
| Net Debt 2024 * | 14.62B 1,171B | Net Debt 2025 * | 12.12B 970B | EV / Sales 2025 * | 1.7 x |
| P/E ratio 2024 * |
11.1
x | P/E ratio 2025 * |
10.3
x | Employees | 35,737 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Teva Pharmaceutical Industries Limited
More recommendations
More press releases
More news
| 1 day | +4.23% | ||
| 1 week | +7.39% | ||
| Current month | -2.13% | ||
| 1 month | -2.33% | ||
| 3 months | +15.95% | ||
| 6 months | +66.99% | ||
| Current year | +32.28% |
1 week
12.69
13.98
1 month
12.5114.47
Current year
10.4514.47
1 year
7.0914.47
3 years
6.7814.47
5 years
6.0715.72
10 years
6.0772.31
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 31/12/22 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 21/12/19 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 31/08/15 |
Janet Vergis
BRD | Director/Board Member | 60 | 08/06/20 |
Sol Barer
CHM | Chairman | 76 | 31/12/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.38% | 13 M€ | -.--% | ||
| 0.27% | 18 M€ | +3.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 13.81 | +4.23% | 10,278,701 |
| 25/04/24 | 13.25 | +1.84% | 8,522,328 |
| 24/04/24 | 13.01 | 0.00% | 7,499,725 |
| 23/04/24 | 13.01 | +1.01% | 8,982,074 |
| 22/04/24 | 12.88 | +0.16% | 7,945,162 |
Delayed Quote Nyse, April 26, 2024 at 09:00 pm
More quotes
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
Pharmaceuticals
Calendar
08/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
13.81
USD
Average target price
15.74
USD
Spread / Average Target
+13.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.28% | 15.64B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- TEVA Stock
